- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07763418
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
A Phase 1, Multi-center, Single-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
The purpose of this study is to assess the pharmacokinetics and safety of golcadomide (BMS-986369) in matched healthy participants with normal renal function, adult participants with severe renal impairment, and participants with end-stage renal disease.
Studieoversigt
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: First line of the email MUST contain NCT # and Site #.
Undersøgelse Kontakt Backup
- Navn: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Telefonnummer: 855-907-3286
- E-mail: Clinical.Trials@bms.com
Studiesteder
-
-
Arizona
-
Chandler, Arizona, Forenede Stater, 85225
- Rekruttering
- Arizona Clinical Trials - Chandler
-
Kontakt:
- Anita Kohli, Site 0003
- Telefonnummer: 434-825-0921
-
-
Florida
-
Miami Lakes, Florida, Forenede Stater, 33014
- Rekruttering
- Panax Clinical Research
-
Kontakt:
- Robert Perry, Site 0002
- Telefonnummer: 305-698-4500
-
Orlando, Florida, Forenede Stater, 32809-3017
- Rekruttering
- Orlando Clinical Research Center OCRC
-
Kontakt:
- Thomas Marbury, Site 0001
- Telefonnummer: 407-257-3462
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participant must have severe renal impairment (RI).
- Participant must have end-stage renal disease (ESRD).
- Participant must be healthy male and female participants not of childbearing potential between 18 and 84 years of age (inclusive) with a BMI between 18 and 40 kg/m2, (inclusive) at screening.
Exclusion Criteria:
- Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).
- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study
- Known or suspected active autoimmune disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
- Other protocol-defined inclusion/exclusion criteria apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Gruppe A
|
Specified dose on specified days
Andre navne:
|
|
Eksperimentel: Gruppe B
|
Specified dose on specified days
Andre navne:
|
|
Eksperimentel: Gruppe C
|
Specified dose on specified days
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Maximum observed concentration (Cmax)
Tidsramme: Up to Day 44
|
Up to Day 44
|
|
Time of maximum observed plasma concentration (Tmax)
Tidsramme: Up to Day 44
|
Up to Day 44
|
|
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Tidsramme: Up to Day 44
|
Up to Day 44
|
|
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Tidsramme: Up to Day 44
|
Up to Day 44
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of participants with adverse events (AEs)
Tidsramme: Up to Day 60
|
Up to Day 60
|
|
Number of participants with serious adverse events (SAEs)
Tidsramme: Up to Day 60
|
Up to Day 60
|
|
Number of participants with physical examination (PE) abnormalities
Tidsramme: Up to Day 44
|
Up to Day 44
|
|
Number of participants with vital sign abnormalities
Tidsramme: Up to Day 44
|
Up to Day 44
|
|
Number of participants with electrocardiogram (ECG) abnormalities
Tidsramme: Up to Day 44
|
Up to Day 44
|
|
Number of participants with clinical safety laboratory abnormalities
Tidsramme: Up to Day 44
|
Up to Day 44
|
|
Dialysate clearance of golcadomide from plasma (CLD)
Tidsramme: Day 1
|
Day 1
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Bristol-Myers Squibb, Bristol-Myers Squibb
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Patologiske processer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Kronisk sygdom
- Sygdomsegenskaber
- Nyreinsufficiens
- Nyreinsufficiens, kronisk
- Patologiske tilstande, tegn og symptomer
- Nyresvigt, kronisk
Andre undersøgelses-id-numre
- CA073-1033
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD-delingstidsramme
See Plan Description
IPD-delingsadgangskriterier
See Plan Description
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .